Cabotegravir and Rilpivirine (Cabenuva®)

Cabenuva (cabotegravir + rilpivirine) is covered as a complete injectable ART to replace a current antiretroviral regimen in adults (≥18) with HIV‑1 who are virologically suppressed (HIV‑1 RNA <50 copies/mL) and have no history of treatment failure or known/suspected resistance — it is excluded for patients <18, those not virologically suppressed, treatment‑naive patients, or those with prior failure/resistance. Approval requires documentation of age, HIV‑1 diagnosis and viral load <50 at initiation and renewal, completion/tolerance of a 1‑month oral lead‑in with Vocabria+Edurant, prescription by or consultation with an HIV specialist, and is authorized for 12 months with specified IM loading and monthly dosing.

"Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace their current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA..."